3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasms
1
Meningioma
1
Malignant Female Reproductive System Neoplasm
1
Hemangiosarcoma
1
Fallopian Tube Neoplasms
1
Ependymoma
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Cyclophosphamide
9
fludarabine
7
Dexamethasone
7
pomalidomide
6
Rituximab
6
pembrolizumab
5
selinexor
4
obinutuzumab
4
glofitamab
4
Lenalidomide
4
daratumumab
3
belantamab mafodotin
3
Temozolomide
3
Gemcitabine
3
Etoposide
3
Bortezomib
3
zanubrutinib
2
venetoclax
2
tocilizumab
2
fludarabine phosphate
2
enzalutamide
2
cemiplimab
2
carfilzomib
2
abemaciclib
2
PF06821497
2
Mesna
2
Lisaftoclax
2
Injections
2
Immunotherapy, Adoptive
2
Granulocyte Colony-Stimulating Factor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Recurrence
×
neratinib
×
30 days
×
Clear all
No trials found.